Blocking of Histamine Release and IgE Binding to FcepsilonRI on Human Basophils by Antibodies Produced in Camels.
10.4168/aair.2015.7.6.583
- Author:
Al Qaoud KHALED
1
;
Yousef SANA
;
Rawashdeh ABDULRAHMAN
;
Khalil RAIDA
;
Abdel Hafez SAMI
Author Information
1. Department of Biological Sciences-Yarmouk University, Irbid, Jordan. khaled@monojo.com.jo
- Publication Type:Original Article
- Keywords:
Camels;
antibodies;
blocking;
immunoglobulin E;
anti-IgE antibodies;
asthma;
histamine release
- MeSH:
Antibodies*;
Antibodies, Blocking;
Asthma;
Basophils*;
Camels*;
Electrophoresis, Polyacrylamide Gel;
Enzyme-Linked Immunosorbent Assay;
Flow Cytometry;
Histamine Release*;
Histamine*;
Humans*;
Hypersensitivity;
Immunoglobulin E*;
Immunoglobulin G;
Passive Cutaneous Anaphylaxis;
Staphylococcal Protein A
- From:Allergy, Asthma & Immunology Research
2015;7(6):583-589
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The production of camel heavy-chain antihuman IgE (huIgE) that has the potential to block IgE-FcepsilonRI interaction and histamine release by basophils. METHODS: Camels were immunized with a synthetic loop peptide (SLP) designed in a multiple antigen peptide system (MAPS) forming SLP-MAPS immunogen. Camel polyclonal antibodies (PCAs) were produced, purified, characterized using Protein A & G, ELISA, and SDS-PAGE, and tested for their potency to block passive sensitization and histamine release of human basophils using flow cytometry (FCM) and ELISA, respectively. RESULTS: FCM data indicated that camel conventional (IgG1) and heavy chain antibodies (HCAbs; IgG2, and IgG3) had blocking activities of 43.9%, 72%, and 96.6%, respectively. Moreover, both IgG2 and IgG3 achieved remarkable inhibition rates of 93.98% and 97.05% in histamine release, respectively, whereas the IgG1inhibiting activity was 60.05%. CONCLUSIONS: Camel PCAs produced against SLP-MAPS were capable of blocking the IgE-receptor interaction and the release of histamine by basophils with superiority to HCAbs. These findings may pave the way toward the possible use of camel anti-huIgE HCAbs as blocking antibodies in the treatment of IgE-mediated allergy and asthma.
